Quest Diagnostics and LabCorp, two of the biggest laboratory diagnostics outfits around, will not accept any blood samples from patients suspected of having the Ebola virus.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
A year ago, Myriad Genetics launched its MyRisk Hereditary Cancer multi-gene molecular diagnostic test with great fanfare. Now, the Utah-based company is touting some eye-popping clinical trial results in a bid to reinforce its utility in the marketplace.
POPULAR COMMENT THREADS
For the medical diagnostics industry, 2014 is looking like a seesaw in terms of venture investment trends.
Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
Xagenic, a startup focused on developing a quick, automated, lab-free molecular diagnostic system, has dipped into the life sciences entrepreneurial world to hire its president and CEO.
Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.
A subsidiary of French in vitro diagnostics giant bioMérieux gained Medicare coverage for a new breast cancer test, a vital milestone necessary to compete in today's market.
Virginia Tech researchers believe they've found a possible biomarker to help detect a rare genetic disease known as severe combined immunodeficiency, or SCID, which leaves patients needing to avoid all human contact and breathe filtered air in order to survive.
From Our Sister Sites
To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.
GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.